These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis. Fierbinteanu-Braticevici C; Dragomir P; Tribus L; Negreanu L; Bengus A; Usvat R; Andronescu D J Gastrointestin Liver Dis; 2006 Dec; 15(4):337-42. PubMed ID: 17205144 [TBL] [Abstract][Full Text] [Related]
45. A Patient with Dilated Cardiomyopathy and Portal Hypertension: Which Beta-Blocker to Use? Sarkar R; Paul R; Roy D; Saha A; Sau TJ; Mondal J J Assoc Physicians India; 2017 Sep; 65(9):107. PubMed ID: 29313593 [No Abstract] [Full Text] [Related]
46. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. Miki S; Masumura H; Kaifu Y; Yuasa S J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982 [TBL] [Abstract][Full Text] [Related]
47. [The use of anaprilin for the correction of portal hypertension in liver cirrhosis]. Bondarenko IP; Dubinskiĭ AA; Tereshkin IG Vrach Delo; 1989 Nov; (11):19-22. PubMed ID: 2609578 [TBL] [Abstract][Full Text] [Related]
48. Long term effects of propranolol on portal pressure in cirrhotic patients. Orban-Schiopu AM; Popescu CR Rom J Gastroenterol; 2003 Mar; 12(1):25-30. PubMed ID: 12673376 [TBL] [Abstract][Full Text] [Related]
49. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Bank AJ; Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM Am J Hypertens; 2007 Jul; 20(7):777-83. PubMed ID: 17586413 [TBL] [Abstract][Full Text] [Related]
50. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Langdon CG; Baxter GA; Young PH J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S51-6. PubMed ID: 1721980 [TBL] [Abstract][Full Text] [Related]
51. [Use of ednit in the treatment of portal hypertension in patients with chronic hepatitis and liver cirrhosis]. Maev IV; Kaziulin AN; Andreev NG; Aksel'rod AG; Nikushkina IN Ter Arkh; 2001; 73(10):79-83. PubMed ID: 11763526 [TBL] [Abstract][Full Text] [Related]
52. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus. Fardoun RZ Pharmacotherapy; 2006 Oct; 26(10):1491-500. PubMed ID: 16999659 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Marchi F; Ciriello G Adv Ther; 1995; 12(4):212-21. PubMed ID: 10155349 [TBL] [Abstract][Full Text] [Related]
54. Carvedilol: a new approach to antihypertensive therapy. Proceedings from International Symposium on Carvedilol. Berlin, March 14-17, 1991. Clin Investig; 1992; 70 Suppl 1():S1-131. PubMed ID: 1350477 [No Abstract] [Full Text] [Related]
60. [Effect of compound Salvia pill combined with propanolol on liver fibrosis and portal hypertension]. Liang YG; Chu XJ Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 May; 22(5):382-3. PubMed ID: 12584844 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]